These results indicate that novel imidazolyl and methylimidazole imidazotetrazinones 377 and 465 inhibit the growth of tumor cells irrespective of MGMT and MMR; of note, 465 demonstrated superior activity (~2-fold) against TMZ-resistant cells guiding compound concentration selection in further experiments. The gene discussed is MRC1; the disease is neoplasm.